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SUMMARY 
For nearly 50 years it has been known that the complement system is activated during 
immune-complex glomerular disease. Detection of complement deposition in the 
glomerulus using immunochemistry has become an important part of the histological 
analysis of renal biopsies and is key to the diagnosis of many types of glomerulonephritis. 
In recent years it has become evident that complement activation is involved in the 
pathogenesis of other types of renal disease. Complement activation is implicated in 
transplant injury, atypical hemolytic uremic syndrome and progressive tubulointerstitial 
fibrosis. Emergence of this evidence has provided insight into how these diseases 
develop, and has yielded useful diagnostic tools and potential targets for therapeutic 
intervention. Clinicians have, by using plasma-based therapies, unknowingly treated 
abnormalities of the complement system in renal patients for many years. Advances in 
antibody and protein technologies have led to the development of complement inhibitors 
that have been used in phase III clinical studies. More-specific agents and applications 
are likely to be developed over the coming years and are discussed in this Review. 
 
Keywords chronic kidney disease, complement, hemolytic uremic syndrome, 
inflammation, transplantation immunology 
 
REVIEW CRITERIA 
We reviewed the main developments in our understanding of complement activation in 
renal disease over the past 10 years. Particular emphasis has been placed on clinical 
studies and those that significantly contribute to our understanding of the mechanisms of 
kidney injury.  
INTRODUCTION 
The complement system is an important part of the body’s innate immune system. It 
consists of approximately 30 soluble and membrane-bound proteins.1,2 Its primary 
function is the destruction and removal of pathogens, immune complexes and apoptotic 
cells. In addition, its ability to influence the development of adaptive immunity is 
increasingly recognized3 which may affect both native and transplant renal injury. In the 
kidney complement serves an important function in preventing immune complexes from 
accumulating along the glomerular basement membranes. Complement is activated via 
three pathways; the classical, alternative and mannose-binding lectin (MBL) pathways, 
all of which converge at the pivotal component C3 (Figure 1). C3 exerts its biological 
functions through the assembly of the cytopathic membrane pore C5b-9, release of 
anaphylotoxins (C3a and C5a) and the deposition of opsonins (C3b and C4b). The 
anaphylotoxins and opsonins are recognized by cell-surface receptors, through which 
they exert their effects (Table 1). These receptors are predominantly expressed on cells of 
myeloid lineages. Other cell types, including renal epithelia, possess some of these 
receptors but little is known about their function on non-myeloid cells. Humans also 
harbor a series of serum and cell-surface inhibitors that prevent inappropriate or 
excessive production of complement and tissue injury (Table 1 and Figure 2). 
 
Despite the presence of these inhibitors, complement activation occurs in the kidney 
during immune-complex-mediated glomerular diseases; for example, lupus nephritis, 
idiopathic membranous nephropathy and membranoproliferative glomerulonephritis. In 
some of these conditions activation of complement is so marked that there is a detectable 
reduction in the concentration of circulating C3 and C4, the magnitude of which mirrors 
disease activity. Staining for complement proteins is now a routine part of renal biopsy 
analysis. In vitro and animal studies have shown that complement is partially responsible 
for the injury that occurs, and have generated important mechanistic data (recently 
reviewed by Thurman and Holers4).  
 
In this article, we will review new developments in our understanding of how 
complement can influence the development of renal injury. Rather than focusing on 
immune-complex-mediated glomerular disease, we will turn our attention to other forms 
of renal injury in which complement activation might be important. 
 
 
ATYPICAL HEMOLYTIC UREMIC SYNDROME 
Gasser et al. were the first to use, in 1955, the term ‘hemolytic uremic syndrome’ (HUS) 
to describe the association of diarrhea, hemolysis, thrombocytopenia and acute renal 
failure.5 The disease is initiated by injury to endothelial cells, which triggers the 
formation of platelet-rich microthrombi that eventually obstruct the small arterioles and 
capillaries of the glomeruli. We now know that the majority of these cases (90%) occur 
after an enteric infection with bacteria that produces a shigatoxin (verotoxin; e.g. 
Escherichia coli 0157:H7).6 Atypical forms of HUS (accounting for the remaining 10% 
of cases) are not related to shigatoxin activity, and can be sporadic (triggered by other 
types of infection, pregnancy, malignancy or drugs such as ciclosporin) or familial. 
Collectively, atypical cases of HUS have a poor outcome compared with typical forms; 
morbidity and mortality rates are high in atypical HUS, with more than 50% of patients 
either dying or developing renal failure. 7 
 
Reduced serum levels of C3, Factor B and Factor H in sporadic and familial forms of the 
disease were first reported in 1974.8 The finding that C4 levels were normal indicated 
involvement of the alternative pathway of complement activation (Figure 1). It was, 
therefore, proposed that a defect in control of the alternative pathway could underlie 
some cases of familial HUS. Generation of C5b-9 on the cell surface might cause 
endothelium to adopt a pro-thrombotic phenotype, whilst the anaphylotoxins C3a and 
C5a could recruit inflammatory cells to the injured endothelium. This hypothesis was 
proven when mutations in Factor H, a soluble complement inhibitor, were found in 
families with HUS.9,10 
 Factor H is a complex protein, comprising 20 homologous short consensus repeats 
(SCRs) of approximately 60 amino acids each that arose due to gene duplication. The 
SCRs have distinct functions. Some inhibit complement activation, others mediate 
binding to polyanionic proteoglycans on mammalian cell surfaces or in the sub-
endothelial matrix. Factor H binds to C3b, preventing binding of Factor B, destabilizes 
the pre-formed alternative pathway convertase C3bBb, and acts as a cofactor for the 
enzymatic degradation of C3b by the serine protease Factor I.11 To date approximately 65 
different mutations in the Factor H gene have been described in association with HUS 
and account for 30% of cases of atypical HUS.12 In most cases the patients are 
heterozygotic for the mutation and usually have normal levels of circulating Factor H 
protein. The mutations are clustered in the C-terminus SCRs that are primarily involved 
in cell binding, rather than the N-terminus domains involved in complement regulation.13-
15
 This indicates that it is the complement regulatory function at the cell surface that is 
essential in preventing HUS.  
 
If the complement regulatory function of Factor H is important in preventing HUS then 
harboring mutations in other control proteins that either functionally interact with Factor 
H or have a similar function should also confer a predisposition to developing HUS. This 
is the case; mutations in the deactivating enzyme Factor I16,17 and the cell-surface 
inhibitory protein CD46 (membrane cofactor protein)18,19 are also associated with 
atypical HUS, accounting for 5% and 10% of cases respectively. In addition, the presence 
of autoantibodies that inhibit the function of Factor H have been described in sporadic 
cases of HUS, adding further weight to the proposal that non-diarrheal HUS is caused by 
a failure to control complement activation.20 Nonetheless, only about 50% of cases of 
atypical HUS can be attributed to known mutations in complement regulators. Either 
undefined mutations exist in other complement control proteins or there are other 
pathogenic mechanisms at work. The trigger for HUS in these patients, who frequently 
present as adults, remains unknown. 
 
It is important to recognize patients with HUS who have a deficiency in the complement 
regulators as this has implications for prognosis and therapy. Mutation screening is now 
available and should be part of the routine assessment of patients with HUS for which no 
other precipitant is identified. Plasma-based therapies remain the mainstay of treatment 
for atypical HUS, with some evidence to support efficacy (reviewed by Noris and 
Remuzzi21). Administration of plasma replaces defective Factor H or Factor I. Whether 
this should be achieved by plasma exchange or infusion is less clear. Exchange removes 
defective Factor H and any other triggers of endothelial dysfunction and, importantly, 
might be the most practical option for prevention of volume overload or hyperviscosity. 
Long-term plasma-based therapy to maintain remission has been reported.22 
Administration of plasma is less likely to be of benefit to those patients with mutations in 
the cell-surface protein CD46. 
 
LUPUS NEPHRITIS 
The importance of the complement system in the pathogenesis of lupus nephritis has been 
recognized for many years (reviewed by Manderson et al.23). Lupus nephritis is 
characterized by deposition of complement proteins in the glomerulus, predominantly 
those of the classical pathway. Although not invariably, animal studies that limit 
complement activation reduce the extent of glomerular injury in lupus prone mice.24,25 
However, complement is not simply a mediator of tissue injury in lupus nephritis but has 
a complex role in the initiation of autoimmunity. Deficiencies in the early classical 
pathway components C1, C2 and C4 predispose people to the development of systemic 
lupus erythematosis (SLE). Patients with a deficiency in C1q, the earliest component of 
the classical pathway, develop severe early onset SLE. Mice with an engineered 
deficiency in C1q also develop a proliferative glomerulonephritis and increased 
autoantibody titers.26,27 One possible explanation for this is that the C1q deficient mice 
have impaired  clearance of apoptotic cells28, which accumulate within the glomeruli. 
Complement is deposited on the surface of these cells facilitating their efficient removal 
by phagocytes, maintaining tissue integrity without initiating an inflammatory response. 
Blebs on the surface of apoptotic cells contain nuclear material and, therefore, many of 
the lupus autoantigens. Therefore, the predisposition of C1q-deficient patients to develop 
SLE could be due to a failure to clear a rich source of autoantigen. Another explanation is 
that opsonization of apoptotic cells might favor their uptake by more-tolerogenic 
immature dendritic cells.29 MBL could serve a similar function, binding to apoptotic 
cells, activating complement and promoting clearance.30 Allelic variants in MBL have 
been associated with SLE, particularly lupus nephritis.31 
 
Autoantibodies against both C1q and MBL have been detected in SLE patients. Anti-C1q 
titers predict disease activity, in particular glomerular inflammation32, whereas levels of 
antibodies against MBL do not.33 Proof that anti-C1q antibodies are pathogenic in 
humans is lacking; however, increasing amounts of data from animal studies indicate that 
they are. Anti-C1q antibodies can be eluted from the glomeruli of lupus-prone mice prior 
to the development of histological disease.34 Injection of anti-C1q antibodies into mice 
depletes circulating C1q, and leads to glomerular deposition of antibody and 
complement35.  
 
COMPLEMENT IN OTHER GLOMERULAR DISEASES 
Complement activation due to the presence of nephritic factor occurs in 
membranoproliferative glomerulonephritis (MPGN) type II. Inherited forms of MPGN II 
are caused by mutations in Factor H.36 Unlike patients with atypical HUS, who are 
usually heterozygotic for mutations in Factor H, affected individuals with MPGN are  
homozygotic (or compound heterozygotes) for mutations in Factor H that result in 
reduced circulating levels of Factor H, uncontrolled activation of the alternative pathway 
and therefore very low levels of ciculating C3. Both pigs with naturally occurring Factor 
H deficiency37 and mice with an engineered  Factor H deficiency develop a similar 
MPGN phenotype. Studies have confirmed that complement activation is essential for the 
development of disease in these models.38 Patients with nephritic factor or Factor H 
deficiency share an inability to control complement activation that results in disruption of 
glomerular structure. The use of regular plasma infusions, replacing absent Factor H, to 
maintain remission in MPGN II has recently been reported.39 As has recently been 
reported for a patient with atypical HUS as a consequence of a Factor H mutation40, liver 
transplantation, perhaps combined a kidney transplant, represents a potential treatment 
for patients with MPGN related to Factor H deficiency. 
 
Products of complement activation can be found in the glomeruli of patients with diabetic 
nephropathy. Glycosylation of the complement regulator CD59 occurs in diabetic 
patients, resulting in a loss of inhibitory function.41 Using an antibody specific for 
glycosylated CD59, this regulator was found to co-localize with C5b-9 in tissues from 
diabetic patients.42 How glycosylated CD59 contributes to the development of diabetic 
complications remains unknown.  
 
PROGRESSIVE PROTEINURIC RENAL DISEASE 
The link between proteinuria, tubulointerstitial fibrosis and a progressive decline in renal 
function is well established.43 What is less well understood is the mechanism linking the 
primary glomerular lesion and/or proteinuria with the subsequent interstitial fibrosis. 
There is evidence that leaked serum proteins alter tubular epithelial cell function, thereby 
promoting a pro-fibrotic phenotype. This might be due to the quantity of protein within 
the tubules overloading the tubular absorptive capacity or to specific proteins in the 
filtrate (e.g. those of the complement system). Products of complement activation such as 
C5b-9 can be found in the urine of proteinuric patients even when the glomerular lesion is 
not typically associated with complement activation (e.g. in diabetic nephropathy).44 This 
strongly indicates that complement activation occurs within the tubular compartment. 
Proximal tubular epithelial cells have an intrinsic capacity to activate complement45—a 
capacity that is possibly related to their production of ammonia46—and a relative paucity 
of complement inhibitors on their apical surface.47 In a human biopsy series there was a 
spatial association between complement deposition and tubulointerstitial expansion and 
cellular infiltration.48 Studies in rats have shown that inherited deficiency49,50, depletion51 
or inhibition52,53 of complement limits the tubulointerstitial injury associated with 
experimental proteinuria and helps to preserve function. Protection from injury is also 
observed in complement (C3) knockout mice.54 These studies have confirmed both the 
predominant role of the alternative pathway in development of renal damage, and the 
importance of endogenous inhibitors in prevention of injury.55 A study in rats using a 
complement inhibitor targeted to the apical membrane of tubular epithelial cells showed 
almost complete protection from loss of clearance function during proteinuria.56 This 
work clearly demonstrates the potential of complement-inhibitory strategies to slow the 
progression of proteinuric renal disease.  
 
It is not known exactly how complement activation causes tubulointerstitial injury. 
Complement, through C5b-9, might directly cause cell lysis or, perhaps more likely, sub-
lytic amounts of C5b-9 on epithelial cells could induce a change in cell phenotype and 
expression of pro-inflammatory and pro-fibrotic cytokines. Alternatively, generation of 
anaphylotoxins might induce chemotaxis of leukocytes such that they move into the 
interstitium or exert direct effects on the epithelium.57 Knowing more about the 
mechanism of injury would allow specific effector pathways to be targeted 
therapeutically. 
 
COMPLEMENT IN TRANSPLANTATION 
The involvement of complement in hyperacute rejection of transplanted tissue when pre-
formed allo-specific or xeno-specific antibodies are present is well recognized but, with 
the advent of improved crossmatching techniques, this is now a rare occurrence. There is, 
however, increasing evidence that complement activation can influence transplantation 
outcome by other mechanisms. Ischemia–reperfusion injury can occur after any period of 
organ hypoperfusion, including after kidney transplantation and surgical interruption to 
renal blood supply. Ischemia lowers the resistance of the endothelium to complement 
attack, and might expose complement-activating surfaces including ligands for MBL58 
and possibly autoantigens.59 Studies in animals have shown that reduced complement 
activity lessens the degree of functional and histological disturbance following a period 
of renal ischemia.60,61 Similar findings have been reported in cardiac ischemia, and phase 
III clinical studies have confirmed that complement inhibition can ameliorate damage 
after myocardial infarction and revascularization.62,63 Whether complement inhibition 
would improve post-transplantation renal function and reduce subsequent adaptive 
immune responses against the graft is yet to be established. 
 
For many years research into the mechanisms and treatment of acute rejection has 
focused on adaptive cellular immunity. There is, however, now more widespread 
recognition of the humoral response as a cause of both acute and chronic injury. The 
presence of donor-specific antibodies is associated with rejection, but these antibodies 
can rarely be found by immunochemical staining of tissue from a transplanted kidney that 
is being rejected. The pathogenic role of donor-specific antibodies has, therefore, been 
questioned. Even transient binding of antibody would, however, be sufficient to activate 
complement through the classical pathway. Activated complement would be degraded by 
the inhibitory serine protease Factor I. When C4 is degraded, a 41-kDa peptide (C4d) 
remains covalently linked to the cell surface, where it acts as an indicator of activation of 
the classical pathway and, therefore, of antibody binding that can persist for weeks.64 The 
development of antibodies that can specifically recognize C4d has facilitated its 
immunochemical detection on biopsy tissue from transplanted organs. C4d has, therefore, 
emerged as a marker of donor-specific antibody deposition. 
 
The presence of C4d-positive staining in a transplant biopsy is closely associated, 
although not invariably, with the presence of donor-specific antibodies, and was first 
noted in patients with vascular rejection of kidney allografts.65 In this study, the presence 
of C4d in a biopsy was associated with worse kidney survival at 1 year (57%) than the 
absence of C4d (1-year graft survival, 90%).66 Presence of C4d in the peritubular 
capillaries, and not on the tubular basement membrane, is useful in distinguishing acute 
humoral rejection from acute cellular rejection.67 Several studies have confirmed that C4d 
staining can identify patients with a humoral element to their rejection of a transplanted 
kidney and, therefore, a worse renal prognosis.68,69 C4d staining is now included in the 
Banff scoring criteria for assessment of renal transplant pathology.70 The Banff scoring 
system recognizes that C4d staining can be positive in the absence of other evidence of 
acute rejection; for example, acute tubular necrosis.70 C4d staining can also be positive in 
patients with chronic allograft nephropathy71, particularly in the glomerular lesion, 
although the implication of this finding is less clear. Although there is general consensus 
that patients with rejection and positive C4d staining require more-intense 
immunosuppression there is, at present, relatively few trial data to guide the choice of 
immunosuppressive regimen. Success has been reported with plasmapheresis, 
immunoadsorption, anti-CD20 monoclonal antibody and intravenous immunoglobulin, 
alone or in combination, but controlled trial data are lacking. C4d will also be generated 
as a consequence of MBL pathway activation. Berger et al reported a worse outcome 
after renal transplantation in patients with high circulating concentrations of MBL72 but 
how this affects transplant function is not known. 
 
LOCAL COMPLEMENT SYNTHESIS IN RENAL DISEASE  
The main source of most circulating complement proteins is the liver. The kidney does, 
however, have the capacity to synthesize a significant amount of complement, 
particularly C3.73 C3 is a large protein with a molecular weight of 185kDa and 
hepatically-synthesized C3 may have limited distribution outside the vascular space. 
Therefore locally synthesized C3 may be the predominant source of this protein within 
the tissue microenvironment despite an excess of C3 within the circulation.  
 
Studies in mice have shown that locally synthesized C3 greatly increases the tempo of 
acute rejection of transplanted organs. When C3 was produced within a transplanted 
kidney, median graft survival was 12.5 days; when C3 was not produced locally, median 
graft survival was more than 100 days.74 A deleterious role for local renal production of 
C3 has also been demonstrated during ischemia–reperfusion injury.75 The potential for 
local C3 synthesis to influence clinical outcomes of transplantation was explored in a 
study that addressed the effect of donor C3 polymorphisms on graft outcomes in 
humans.76 Expression of one of the main human polymorphisms of C3 within the 
transplanted kidney increased 8-year graft survival by more than 30%. Interestingly, this 
effect of the polymorphism was confined to C3 produced within the graft; systemically 
produced C3 harboring the polymorphism was not associated with improved graft 
survival. These findings are in keeping with animal data, and indicate that the site at 
which complement is synthesized is a critical determinant of function. Whether 
knowledge of the C3 allotype of a transplanted kidney can be used to predict outcome 
and, therefore, to guide immunosuppressive treatment, remains to be determined. 
  
Although clearly important in transplantation, a recent study failed to detect a role for 
local production of C3 in glomerular disease. Rather, the investigation indicated that 
circulating complement was an important mediator of injury at this site.77 Whether locally 
generated C3 influences non-transplant interstitial disease is generally unknown. One 
exception is pyelonephritis, during which complement opsonization of bacteria enhances 
bacterial invasion of an epithelial monolayer in a mouse model of the disease.78 C3 
produced locally by the epithelial cells is sufficient to promote bacterial invasion. C3b on 
the bacterial surface is then recognized by epithelial receptors, probably CD46 in 
humans,79 leading to active uptake of bacteria into cells, which helps establish infection. 
 
COMPLEMENT INHIBITORS IN CLINICAL MEDICINE 
Manipulation of the complement system is a potential therapeutic strategy in many 
inflammatory diseases, not only those discussed in this Review. As well as knowing 
which groups of patients are likely to benefit from inhibition, we are increasingly able to 
identify which components of the complement system to target, thereby avoiding the 
potential risks, in particular higher rates of infection, associated with complete inhibition. 
The tools needed to inhibit complement are now available, but are still far from providing 
a full range of therapeutic options. Many of the therapeutics are based on endogenous 
inhibitors. Soluble complement receptor 1 (sCR1) is the best known of these. It is 
generated by deleting the transmembrane domain of CR1.80 Numerous studies have 
consistently shown that complement inhibition using sCR1 can ameliorate tissue injury 
(reviewed by Mollnes and Kirschfink81). In humans, sCR1 has been tested with some 
success in lung transplantation82 and cardiopulmonary bypass83, but did not improve the 
outcome of adult respiratory distress syndrome.84 Administered intravenously, it has a 
relatively short half-life (hours) and is, therefore, only suitable for the treatment of acute 
conditions. Adding a lipid tail to a shortened form of sCR1 targets it to cell membranes, 
where it effectively inhibits complement activation,85 and might enhance its 
effectiveness. Soluble forms of CD46, decay accelerating factor and CD59 have also 
been made but have not, as far as we are aware, been used in humans. 
 
Another approach to therapeutic manipulation of complement is the use of antibodies to 
block complement protein function. Development of an anti-C5 antibody is most 
advanced. This antibody has been used in phase III clinical studies in cardiopulmonary 
bypass86 and to prevent tissue damage due to myocardial ischemia.62,63 A humanized 
version of this antibody suitable for long-term use is now available and the result of trials, 
including a study in membranous nephropathy, are awaited. Other antibodies against C5a, 
C5b-9, Factor B and Factor D have all shown efficacy in animal studies81 but have not 
been tested clinically. The most appropriate approach to treatment of chronic diseases is 
the development of small molecules that have good oral bioavailability. Orally active 
inhibitors of C3a and C5a receptors are available and have been used to reduce 
inflammation in animal models87,88. These agents have not, however, been used to treat 
humans. 
 
CONCLUSIONS 
Specialists in nephrology, perhaps more than those in any other branch of medicine, have 
been aware of the potential of the complement system to influence disease. Until recently 
this awareness has largely been confined to immune-complex-mediated glomerular 
disease. This is now changing and, in renal disease—as in many other areas—
complement biology is enjoying a renaissance. Complement activation might contribute 
to other forms of renal injury including non-immune-complex-mediated glomerular 
disease, progressive interstitial fibrosis and rejection of transplanted kidneys. We are 
adding to the list of diseases in which complement is involved, as well as advancing our 
understanding of the nature of the role of complement in these conditions. This enhanced 
knowledge, coupled with generation of methods of inhibiting complement activation, 
could produce new insights into disease pathogenesis and guide the development of 
effective complement-based treatment strategies. We are still some way from having 
inhibitors that can effectively be used to treat patients in routine clinical practice. 
Nevertheless, this should remain the goal of ongoing research in this field. 
 
Reference List 
 
 1.  Walport,M.J.(2001) Complement. Second of two parts. N Engl J Med 344, 1140-
1144 . 
 2.  Walport,M.J.(2001) Complement. First of two parts. N Engl J Med 344, 1058-
1066 . 
 3.  Carroll,M.C.(2004) The complement system in regulation of adaptive immunity. 
Nat. Immunol 5, 981-986 . 
 4.  Thurman,J.M. and Holers,V.M.(2006) Complement and Kidney Disease pp. 49-
63. Zipfel,P.F. (ed.), Birkhauser Verlag, Basel. 
 5.  Gasser,C. et al.(1955) [Hemolytic-uremic syndrome: bilateral necrosis of the 
renal cortex in acute acquired hemolytic anemia.]. Schweiz. Med Wochenschr. 85, 
905-909 . 
 6.  Constantinescu,A.R. et al.(2004) Non-enteropathic hemolytic uremic syndrome: 
causes and short-term course. Am J Kidney Dis. 43, 976-982 . 
 7.  Noris,M. et al.(1999) Hypocomplementemia discloses genetic predisposition to 
hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of 
factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic 
Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 10, 
281-293 . 
 8.  Stuhlinger,W. et al.(1974) Letter: Haemolytic-uraemic syndrome: evidence for 
intravascular C3 activation. Lancet 2, 788-789 . 
 9.  Warwicker,P. et al.(1997) Three new polymorphisms in the human complement 
factor H gene and promoter region. Immunogenetics 46, 437-438 . 
 10.  Warwicker,P. et al.(1998) Genetic studies into inherited and sporadic hemolytic 
uremic syndrome. Kidney Int. 53, 836-844 . 
 11.  Rodriguez,d.C. et al.(2004) The human complement factor H: functional roles, 
genetic variations and disease associations. Mol. Immunol 41, 355-367 . 
 12.  Caprioli,J. et al.(2006) Genetics of HUS: the impact of MCP, CFH, and IF 
mutations on clinical presentation, response to treatment, and outcome. Blood 
108, 1267-1279 . 
 13.  Jokiranta,T.S. et al.(2005) Binding of complement factor H to endothelial cells is 
mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 
167, 1173-1181 . 
 14.  Manuelian,T. et al.(2003) Mutations in factor H reduce binding affinity to C3b 
and heparin and surface attachment to endothelial cells in hemolytic uremic 
syndrome. J Clin. Invest 111, 1181-1190 . 
 15.  Jozsi,M. et al.(2006) Factor H and atypical hemolytic uremic syndrome: 
mutations in the C-terminus cause structural changes and defective recognition 
functions. J Am Soc Nephrol 17, 170-177 . 
 16.  Fremeaux-Bacchi,V. et al.(2004) Complement factor I: a susceptibility gene for 
atypical haemolytic uraemic syndrome. J Med Genet. 41, e84 . 
 17.  Kavanagh,D. et al.(2005) Mutations in complement factor I predispose to 
development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16, 2150-
2155 . 
 18.  Richards,A. et al.(2003) Mutations in human complement regulator, membrane 
cofactor protein (CD46), predispose to development of familial hemolytic uremic 
syndrome. Proc. Natl. Acad. Sci U. S. A 100, 12966-12971 . 
 19.  Noris,M. et al.(2003) Familial haemolytic uraemic syndrome and an MCP 
mutation. Lancet 362, 1542-1547 . 
 20.  Dragon-Durey,M.A. et al.(2005) Anti-Factor H autoantibodies associated with 
atypical hemolytic uremic syndrome. J Am Soc Nephrol 16, 555-563 . 
 21.  Noris,M. and Remuzzi,G.(2005) Genetic abnormalities of complement regulators 
in hemolytic uremic syndrome: how do they affect patient management? Nat. 
Clin. Pract. Nephrol 1, 2-3 . 
 22.  Stratton,J.D. and Warwicker,P.(2002) Successful treatment of factor H-related 
haemolytic uraemic syndrome. Nephrol Dial. Transplant. 17, 684-685 . 
 23.  Manderson,A.P. et al.(2004) The role of complement in the development of 
systemic lupus erythematosus. Annu. Rev. Immunol 22, 431-456 . 
 24.  Bao,L. et al.(2002) Transgenic expression of a soluble complement inhibitor 
protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 
168, 3601-3607 . 
 25.  Bao,L. et al.(2003) Administration of a soluble recombinant complement C3 
inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 14, 
670-679 . 
 26.  Botto,M. et al.(1998) Homozygous C1q deficiency causes glomerulonephritis 
associated with multiple apoptotic bodies. Nat. Genet. 19, 56-59 . 
 27.  Mitchell,D.A. et al.(1999) Cutting edge: C1q protects against the development of 
glomerulonephritis independently of C3 activation. J Immunol 162, 5676-5679 . 
 28.  Taylor,P.R. et al.(2000) A hierarchical role for classical pathway complement 
proteins in the clearance of apoptotic cells in vivo. J Exp. Med 192, 359-366 . 
 29.  Nauta,A.J. et al.(2004) Opsonization with C1q and mannose-binding lectin targets 
apoptotic cells to dendritic cells. J Immunol 173, 3044-3050 . 
 30.  Nauta,A.J. et al.(2003) Mannose-binding lectin engagement with late apoptotic 
and necrotic cells. Eur. J Immunol 33, 2853-2863 . 
 31.  Garred,P. et al.(2001) Association of mannose-binding lectin gene variation with 
disease severity and infections in a population-based cohort of systemic lupus 
erythematosus patients. Genes Immun. 2, 442-450 . 
 32.  Mosca,M. et al.(2006) Prevalence and clinico-serological correlations of anti-
alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic 
lupus erythematosus. J Rheumatol. 33, 695-697 . 
 33.  Seelen,M.A. et al.(2003) Autoantibodies against mannose-binding lectin in 
systemic lupus erythematosus. Clin. Exp. Immunol 134, 335-343 . 
 34.  Trouw,L.A. et al.(2004) Anti-C1q autoantibodies in murine lupus nephritis. Clin. 
Exp. Immunol 135, 41-48 . 
 35.  Trouw,L.A. et al.(2004) Anti-C1q autoantibodies deposit in glomeruli but are 
only pathogenic in combination with glomerular C1q-containing immune 
complexes. J Clin. Invest 114, 679-688 . 
 36.  Appel,G.B. et al.(2005) Membranoproliferative glomerulonephritis type II (dense 
deposit disease): an update. J Am Soc Nephrol 16, 1392-1403 . 
 37.  Hogasen,K. et al.(1995) Hereditary porcine membranoproliferative 
glomerulonephritis type II is caused by factor H deficiency. J Clin. Invest 95, 
1054-1061 . 
 38.  Pickering,M.C. et al.(2002) Uncontrolled C3 activation causes 
membranoproliferative glomerulonephritis in mice deficient in complement factor 
H. Nat. Genet. 31, 424-428 . 
 39.  Licht,C. et al.(2006) Deletion of Lys224 in regulatory domain 4 of Factor H 
reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 
70, 42-50 . 
 40.  Saland,J.M. et al.(2006) Favorable long-term outcome after liver-kidney 
transplant for recurrent hemolytic uremic syndrome associated with a factor H 
mutation. Am J Transplant. 6, 1948-1952 . 
 41.  Acosta,J. et al.(2004) Complement and complement regulatory proteins as 
potential molecular targets for vascular diseases. Curr. Pharm. Des 10, 203-211 . 
 42.  Qin,X. et al.(2004) Glycation inactivation of the complement regulatory protein 
CD59: a possible role in the pathogenesis of the vascular complications of human 
diabetes. Diabetes 53, 2653-2661 . 
 43.  Mackensen-Haen,S. et al.(1992) The consequences for renal function of widening 
of the interstitium and changes in the tubular epithelium of the renal cortex and 
outer medulla in various renal diseases. Clin. Nephrol 37, 70-77 . 
 44.  Morita,Y. et al.(2000) Complement activation products in the urine from 
proteinuric patients. J Am Soc Nephrol 11, 700-707 . 
 45.  Camussi,G. et al.(1982) In vitro alternative pathway activation of complement by 
the brush border of proximal tubules of normal rat kidney. J Immunol 128, 1659-
1663 . 
 46.  Nath,K.A. et al.(1991) Increased ammoniagenesis as a determinant of progressive 
renal injury. Am J Kidney Dis. 17, 654-657 . 
 47.  Ichida,S. et al.(1994) Localization of the complement regulatory proteins in the 
normal human kidney. Kidney Int 46, 89-96 . 
 48.  Mosolits,S. et al.(1997) Membrane attack complex and membrane cofactor 
protein are related to tubulointerstitial inflammation in various human 
glomerulopathies. Nephron 75, 179-187 . 
 49.  Nangaku,M. et al.(2002) C6 mediates chronic progression of tubulointerstitial 
damage in rats with remnant kidneys. J Am Soc Nephrol 13, 928-936 . 
 50.  Nangaku,M. et al.(1999) Complement membrane attack complex (C5b-9) 
mediates interstitial disease in experimental nephrotic syndrome. J Am Soc 
Nephrol 10, 2323-2331 . 
 51.  Nomura,A. et al.(1997) Role of complement in acute tubulointerstitial injury of 
rats with aminonucleoside nephrosis. Am J Pathol 151, 539-547 . 
 52.  Nomura,A. et al.(1997) Role of complement in acute tubulointerstitial injury of 
rats with aminonucleoside nephrosis. Am J Pathol 151, 539-547 . 
 53.  Morita,Y. et al.(1997) The role of complement in the pathogenesis of 
tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am 
Soc Nephrol 8, 1363-1372 . 
 54.  Welch,T.R. and Blystone,L.W.(2005) C3 is central to the interstitial component of 
experimental immune complex glomerulonephritis. Clin. Immunol 115, 80-84 . 
 55.  Turnberg,D. et al.(2006) Complement activation contributes to both glomerular 
and tubulointerstitial damage in adriamycin nephropathy in mice. J Immunol 177, 
4094-4102 . 
 56.  He,C. et al.(2005) Complement inhibitors targeted to the proximal tubule prevent 
injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. 
J Immunol 174, 5750-5757 . 
 57.  Welch,T.R. et al.(2002) C5a is important in the tubulointerstitial component of 
experimental immune complex glomerulonephritis. Clin. Exp. Immunol 130, 43-
48 . 
 58.  de Vries,B. et al.(2004) The mannose-binding lectin-pathway is involved in 
complement activation in the course of renal ischemia-reperfusion injury. Am J 
Pathol 165, 1677-1688 . 
 59.  Zhang,M. et al.(2006) Identification of the target self-antigens in reperfusion 
injury. J Exp. Med. 203, 141-152 . 
 60.  Farrar,C.A. et al.(2004) Independent pathways of P-selectin and complement-
mediated renal ischemia/reperfusion injury. Am J Pathol 164, 133-141 . 
 61.  Zhou,W. et al.(2000) Predominant role for C5b-9 in renal ischemia/reperfusion 
injury. J Clin. Invest 105, 1363-1371 . 
 62.  Granger,C.B. et al.(2003) Pexelizumab, an anti-C5 complement antibody, as 
adjunctive therapy to primary percutaneous coronary intervention in acute 
myocardial infarction: the COMplement inhibition in Myocardial infarction 
treated with Angioplasty (COMMA) trial. Circulation 108, 1184-1190 . 
 63.  Mahaffey,K.W. et al.(2003) Effect of pexelizumab, an anti-C5 complement 
antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the 
COMPlement inhibition in myocardial infarction treated with thromboLYtics 
(COMPLY) trial. Circulation 108, 1176-1183 . 
 64.  Nickeleit,V. et al.(2002) Detection of the complement degradation product C4d in 
renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 13, 
242-251 . 
 65.  Feucht,H.E. et al.(1991) Vascular deposition of complement-split products in 
kidney allografts with cell-mediated rejection. Clin. Exp. Immunol 86, 464-470 . 
 66.  Feucht,H.E. et al.(1993) Capillary deposition of C4d complement fragment and 
early renal graft loss. Kidney Int 43, 1333-1338 . 
 67.  Collins,A.B. et al.(1999) Complement activation in acute humoral renal allograft 
rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am 
Soc Nephrol 10, 2208-2214 . 
 68.  Herzenberg,A.M. et al.(2002) C4d deposition in acute rejection: an independent 
long-term prognostic factor. J Am Soc Nephrol 13, 234-241 . 
 69.  Bohmig,G.A. et al.(2002) Capillary C4d deposition in kidney allografts: a specific 
marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13, 1091-1099 . 
 70.  Racusen,L.C. et al.(2003) Antibody-mediated rejection criteria - an addition to the 
Banff 97 classification of renal allograft rejection. Am J Transplant. 3, 708-714 . 
 71.  Mauiyyedi,S. et al.(2001) Chronic humoral rejection: identification of antibody-
mediated chronic renal allograft rejection by C4d deposits in peritubular 
capillaries. J Am Soc Nephrol 12, 574-582 . 
 72.  Berger,S.P. et al.(2005) Association between mannose-binding lectin levels and 
graft survival in kidney transplantation. Am J Transplant. 5, 1361-1366 . 
 73.  Tang,S. et al.(1999) Contribution of renal secreted complement C3 to the 
circulating pool in humans. J Immunol 162, 4336-4341 . 
 74.  Pratt,J.R. et al.(2002) Local synthesis of complement component C3 regulates 
acute renal transplant rejection. Nat. Med. 8, 582-587 . 
 75.  Farrar,C.A. et al.(2006) Local extravascular pool of C3 is a determinant of 
postischemic acute renal failure. FASEB J 20, 217-226 . 
 76.  Brown,K.M. et al.(2006) Influence of donor C3 allotype on late renal-
transplantation outcome. N Engl J Med 354, 2014-2023 . 
 77.  Sheerin,N.S. et al.(2006) Accumulation of immune complexes in glomerular 
disease is independent of locally synthesized c3. J Am Soc Nephrol 17, 686-696 . 
 78.  Springall,T. et al.(2001) Epithelial secretion of C3 promotes colonization of the 
upper urinary tract by Escherichia coli. Nat. Med. 7, 801-806 . 
 79.  Li,K. et al.(2006) CD46 (membrane cofactor protein) acts as a human epithelial 
cell receptor for internalization of opsonized uropathogenic Escherichia coli. J 
Immunol 177, 2543-2551 . 
 80.  Weisman,H.F. et al.(1990) Soluble human complement receptor type 1: in vivo 
inhibitor of complement suppressing post-ischemic myocardial inflammation and 
necrosis. Science 249, 146-151 . 
 81.  Mollnes,T.E. and Kirschfink,M.(2006) Strategies of therapeutic complement 
inhibition. Mol. Immunol 43, 107-121 . 
 82.  Keshavjee,S. et al.(2005) A randomized, placebo-controlled trial of complement 
inhibition in ischemia-reperfusion injury after lung transplantation in human 
beings. J Thorac. Cardiovasc. Surg. 129, 423-428 . 
 83.  Li,J.S. et al.(2004) Pharmacokinetics and safety of TP10, soluble complement 
receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J 147, 173-
180 . 
 84.  Zimmerman,J.L. et al.(2000) Phase I trial of the recombinant soluble complement 
receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care 
Med. 28, 3149-3154 . 
 85.  Smith,G.P. and Smith,R.A.(2001) Membrane-targeted complement inhibitors. 
Mol. Immunol 38, 249-255 . 
 86.  Fitch,J.C. et al.(1999) Pharmacology and biological efficacy of a recombinant, 
humanized, single-chain antibody C5 complement inhibitor in patients undergoing 
coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 
100, 2499-2506 . 
 87.  Bao,L. et al.(2005) C5a promotes development of experimental lupus nephritis 
which can be blocked with a specific receptor antagonist. Eur. J Immunol 35, 
2496-2506 . 
 88.  Bao,L. et al.(2005) Signaling through up-regulated C3a receptor is key to the 
development of experimental lupus nephritis. J Immunol 175, 1947-1955 . 
 
Table 1 Complement inhibitors and receptors. 
[Au: please check all changes carefully, and provide definitions for the following; 
EBV, TCC, H (Factor H?), SP-A, FDC, DC (dendritic cell?), AP, CP, iC3b 
(inactivated C3b?)] done either modified in table or defined bellow 
 
Name Function Tissue distribution (concentration) 
Fluid phase 
C1 inhibitor Binds to activated C1r and C1s, 
removing them from C1q Serum (150 g/ml) 
C4b-binding protein 
Accelerates decay of CP C3/C5 
convertase  
Binds C4b, displacing C2b 
Cofactor for cleavage of C4b by 
Factor I 
Serum (150–300 g/ml) 
Factor H  
Controls activity of AP C3/C5 
convertase 
Binds C3b, displacing Bb 
Cofactor for Factor I 
Serum (550 g/ml) 
Factor I  
Cleaves C3b and C4b, aided by 
Factor H, membrane cofactor 
protein, C4b-binding protein or 
complement receptor 1 
Serum (35 g/ml) 
Protein S BindsC5b-9 and prevents insertion 
of membrane attack complex  Serum (25 g/ml) 
Clusterin Binds C5b-9 and prevents insertion 
of membrane attack complex Serum (100–300 g/ml) 
Membrane bound 
Decay accelerating factor 
(CD55) 
Protects host cells from autologous 
complement attack 
Accelerates decay of CP and AP 
C3/C5 convertase  
Present on all blood elements and most 
other cell types 
Membrane cofactor protein 
(CD46) 
Cofactor for cleavage of C3b and 
C4b by Factor I  Present on all cell types except erythrocytes 
CD59 
Binds C8  
Blocks formation of membrane 
attack complex  
Present on all circulating cells, vascular 
endothelium, epithelia, and in most tissues 
Complement receptor 1 
(CD35) 
Binds C3b and C4b, iC3b and C1q 
Stimulates phagocytosis and 
removal of immune complexes 
Accelerates decay of CP and AP 
C3/C4 convertase 
Erythrocytes, macrophages, monocytes, 
polymorphonuclear leukocytes, B cells, 
follicular dendritic cells 
Complement receptor 2 Binds C3d, iC3b, C3dg and EBV B cells, follicular dendritic cells 
(CD21) Component of B-cell co-receptor 
Complement receptor 3 (Mac-
1, CD11b/CD18) 
Binds iC3b 
Stimulates phagocytosis 
Macrophages, monocytes, 
polymorphonuclear leukocytes,  follicular 
dendritic cells 
Complement receptor 4  
Binds iC3b 
Stimulates phagocytosis 
Macrophages, monocytes, 
polymorphonuclear leukocytes, dendritic 
cells 
C5a receptor 
Binds C5a 
Intracellular activator of G proteins 
Endothelial cells, mast cells, phagocytes 
C3a receptor 
Binds C3a 
Intracellular activator of G proteins 
Endothelial cells, mast cells, phagocytes 
C1q receptor 
Interacts with C1q, mannose-
binding lectin, SP-A and collagen 
Enhances phagocytosis 
Broad [Au: widely expressed, including, 
but not restricted to, the following? yes] 
Monocytes, neutrophils, leukocytes, platelets 
 
 
Abbreviations used: AP alternative pathway; CP classical pathway; EBV Epstein-
Barr virus; iC3b inactivated C3b 
Figure 1 The complement cascade. The central step of complement activation is the 
cleavage of C3 (shown in red) into C3b and C3a. The classical pathway (shown in 
purple) is mediated by antibodies, whereas the lectin (dark blue) and alternative (green) 
pathways are triggered by distinct carbohydrate residues on microbes or stressed host 
cells. C3b activation leads to formation of a membrane attack complex (C5b-9) from 
terminal complement components (shown in light blue). The number of C9 molecules (n) 
within the membrane attack complex can vary between 1 and 18. The C3 and C5 
convertases are shown in yellow. Abbreviations: MAC, membrane attack complex; 
MASP, MBL-associated serine protease; MBL, mannose-binding lectin. 
 
Figure 2 Inhibitors of complement activation. The main site of action of the complement 
inhibitors is shown. Both membrane bound (red) and soluble (blue) inhibitors are 
responsible for control both convertase activity and C5b-9 assembly. Inhibitors control 
convertase activity by accelerating the decay of the convertase complex (CD55), 
providing cofactor activity for the serine protease Factor I (CD46, Factor H) or a 
combination of both (CR1, C4bp). Abbreviations: C4bp, C4 binding protein. 
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